# Lymphoma, Follicular trials: 175 new since Nov 2024

Updated October 23, 2026.

175 clinical studies in Lymphoma, Follicular were first posted on ClinicalTrials.gov from November 15, 2024 to October 23, 2026; 52 have an industry sponsor and 125 are recruiting or about to. The newest, NCT07893197, was posted on October 23, 2026: Ceritinib Treatment for Recurrent Meningiomas (Kevin Petrecca).

## The full list

New Lymphoma, Follicular clinical trials: 175 rows for $8.75, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/lymphoma-follicular

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 175
- Industry sponsored: 52
- Recruiting or not yet: 125
- Latest posted: October 23, 2026

## Newest trials

The newest 100 of 175, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07893197 | Ceritinib Treatment for Recurrent Meningiomas | Kevin Petrecca | Phase 2 | Not yet recruiting | Recurrent Meningioma, Grade I and Grade II | 10 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893197) |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | GUSTAVO SALGUERO | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 15, 2026 | NCT07875413 | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B... | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875413) |
| October 13, 2026 | NCT07869797 | Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer... | Mundipharma (China) Pharmaceutical Co. Ltd | Observational | Not yet recruiting | Cancer Pain | 378 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869797) |
| October 1, 2026 | NCT07853040 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment | Incyte Corporation | Phase 1 | Not yet recruiting | Hepatic Insufficiency, Liver Diseases | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853040) |
| September 28, 2026 | NCT07844967 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | 32 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844967) |
| September 28, 2026 | NCT07844811 | Early Redox Biomarker Changes After Stellate Ganglion Block in Traumatic Brain Injury | University Medical Centre Ljubljana | Observational | Completed | Brain Injuries, Traumatic | 20 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844811) |
| September 22, 2026 | NCT07834931 | PMCF Study Fortilink-TC Ti | BAAT Medical Products B.V. | Observational | Recruiting | Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1 | 50 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834931) |
| September 22, 2026 | NCT07834736 | PMCF Study Fortilink-TS Ti | BAAT Medical Products B.V. | Observational | Recruiting | Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1 | 50 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834736) |
| September 18, 2026 | NCT07828730 | Sparrow App Guided Evaluation (SAGE) Vanguard Trial for Aortic Stenosis in Adults Aged Seventy and Older | Sunnybrook Health Sciences Centre | Not applicable | Not yet recruiting | Moderate or Severe Aortic Stenosis | 1,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828730) |
| August 25, 2026 | NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783594) |
| August 21, 2026 | NCT07780097 | TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization | T. John Winhusen, PhD | Not applicable | Enrolling by invitation | Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780097) |
| August 7, 2026 | NCT07752056 | Low-Sodium Diet for Postpartum Blood Pressure Control | Women and Infants Hospital of Rhode Island | Not applicable | Not yet recruiting | Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe, Pre-Eclampsia; Mild, Postpartum | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752056) |
| August 6, 2026 | NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | Natera, Inc. | Observational | Recruiting | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal... | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750886) |
| August 5, 2026 | NCT07747792 | Shorter Treatment Regimen Implementation Evaluation Study | Centre for Infectious Disease Research in Zambia | Observational | Completed | Tuberculosis (TB), Tuberculosis in Children, Tuberculosis Treatment Effectiveness, Tuberculosis Active | 175 | Zambia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747792) |
| July 30, 2026 | NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal... | Australasian Leukaemia and Lymphoma Group | Phase 3 | Not yet recruiting | Follicular Lymphoma | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736950) |
| July 28, 2026 | NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | University of Washington | Phase 2 | Recruiting | Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731789) |
| July 22, 2026 | NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide... | Ruijin Hospital | Phase 3 | Not yet recruiting | Follicular Lymphoma ( FL) | 652 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719855) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | Australia, France, Italy, Poland, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| June 29, 2026 | NCT07673666 | GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) | Deep Learning Institute of Radiological Sciences | Observational | Completed | Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma of Brain, Astrocytoma, Grade II, Astrocytoma, IDH-Mutant, Grade 2... | 1,372 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673666) |
| June 26, 2026 | NCT07671248 | Tirzepatide in the Treatment of Cannabis Use Disorder | McMaster University | Phase 3 | Not yet recruiting | Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | 15 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671248) |
| June 24, 2026 | NCT07664787 | Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study | Ruijin Hospital | Not applicable | Not yet recruiting | Hypertension, Grade 1 | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664787) |
| June 17, 2026 | NCT07653386 | Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis | VinUniversity | Not applicable | Completed | Mild and Moderate Atopic Dermatitis Patients, Atopic Dermatitis (AD) | 90 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653386) |
| June 10, 2026 | NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | Northside Hospital, Inc. | Phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell... | 29 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638982) |
| June 8, 2026 | NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | Follicular Lymphoma | 960 | Argentina, Australia, Chile, China, Greece, Israel, Italy, Poland, South Korea... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634471) |
| June 8, 2026 | NCT07631598 | Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses | Montefiore Medical Center | Not applicable | Recruiting | Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate | 512 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631598) |
| June 5, 2026 | NCT07630545 | A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients. | Mission Therapeutics | Phase 1 | Recruiting | Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease | 106 | Australia, France, Germany, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630545) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 27, 2026 | NCT07609446 | Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | The First Affiliated Hospital of Soochow University | Observational | Not yet recruiting | Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609446) |
| May 20, 2026 | NCT07599033 | Effects of a Progressive Adapted Physical Education Program on Muscular Strength and Endurance in Adolescents With Mild Intellectual... | Inonu University | Not applicable | Completed | Intellectual Disability, Mild, Muscular Strength | 46 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599033) |
| May 19, 2026 | NCT07596186 | Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices | Soroka University Medical Center | Observational | Active not recruiting | Cognitive Decline, Mild | 98 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596186) |
| May 18, 2026 | NCT07592481 | Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors | Centre Hospitalier de la côte Basque | Not applicable | Not yet recruiting | Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL), Waldenstrom Macroglobulinaemia, Lymphoplasmacytic... | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592481) |
| May 14, 2026 | NCT07586722 | Effects of a 12-Week Pickleball Training Program on Cognitive and Motor Skills in Adolescents With Mild Intellectual Disability | Elif Top | Not applicable | Active not recruiting | Intellectual Disability, Mild | 32 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586722) |
| May 14, 2026 | NCT07585851 | Administration of Repurposed Ketoconazole in Glioma Patients | Universitas Padjadjaran | Early phase 1 | Active not recruiting | Diffuse Glioma, Diffuse Glioma, Grade I, Diffuse Glioma, Grade II, Diffuse Glioma, Grade III, Diffuse Glioma, Grade IV | 80 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585851) |
| May 14, 2026 | NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Follicular Lymphoma | 27 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585747) |
| May 1, 2026 | NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular... | Sinocelltech Ltd. | Phase 3 | Recruiting | Follicular Lymphoma (FL) | 93 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562022) |
| April 30, 2026 | NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe... | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559474) |
| April 30, 2026 | NCT07558538 | A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant... | Shanghai Zhongshan Hospital | Early phase 1 | Recruiting | ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558538) |
| April 29, 2026 | NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Follicular Lymphoma | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555470) |
| April 24, 2026 | NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Follicular Lymphoma (FL) | 52 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550855) |
| April 24, 2026 | NCT07550634 | Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment | MindRank AI Ltd | Phase 1 | Not yet recruiting | Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550) | 32 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550634) |
| April 23, 2026 | NCT07548697 | A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548697) |
| April 23, 2026 | NCT07546760 | A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Recruiting | Hepatic Impairment | 28 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546760) |
| April 22, 2026 | NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | Evopoint Biosciences Inc. | Phase 2 | Recruiting | Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A | 65 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545603) |
| April 15, 2026 | NCT07530952 | Green VR for Depression | Sykehuset Innlandet HF | Not applicable | Completed | Depression, Mild or Moderate | 45 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530952) |
| April 14, 2026 | NCT07528781 | Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume | Germans Trias i Pujol Hospital | Observational | Recruiting | Moderate or Severe Mitral Regurgitation | 200 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528781) |
| April 9, 2026 | NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | 280 | Argentina, Australia, Brazil, Canada, Chile, China, France, Germany, Israel... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519772) |
| April 1, 2026 | NCT07505849 | ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma | KeshuZhou | Phase 2 | Not yet recruiting | Follicular Lymphomas | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505849) |
| March 30, 2026 | NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) | Health Institutes of Turkey | Phase 2/3 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse... | 40 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502118) |
| March 24, 2026 | NCT07490925 | Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS | Beijing Chao Yang Hospital | Not applicable | Recruiting | ARDS (Moderate or Severe) | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490925) |
| March 17, 2026 | NCT07476378 | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not applicable | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia... | 69 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476378) |
| March 12, 2026 | NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Mayo Clinic | Phase 1/2 | Recruiting | Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma... | 33 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468136) |
| March 5, 2026 | NCT07451197 | Family-Focused Study to Support Medication for Opioid Use Disorder | University of Wisconsin, Madison | Not applicable | Not yet recruiting | Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | 338 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451197) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| February 20, 2026 | NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Malignancies and Hepatic Impairment | 24 | France, Italy, Spain, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422610) |
| February 19, 2026 | NCT07420062 | Reduced Dosage and/or Visitation Protocol for the Treatment of Acute Malnutrition in Kenya | International Food Policy Research Institute | Not applicable | Not yet recruiting | Acute Malnutrition in Childhood, Acute Malnutrition, Severe, Acute Malnutrition, Moderate, Wasting | 2,274 | Kenya | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420062) |
| February 18, 2026 | NCT07418190 | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Relapsed/Refractory Follicular Lymphoma | 33 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418190) |
| February 17, 2026 | NCT07412405 | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells... | GUSTAVO SALGUERO | Not applicable | Not yet recruiting | Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell... | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412405) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| February 13, 2026 | NCT07410052 | Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination | Center for Health Sciences, Serbia | Not applicable | Not yet recruiting | Cognitive Deficits, Mild | 28 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410052) |
| January 29, 2026 | NCT07375407 | Aerobic Exercise vs Physiological Ischemic Training in Stage 2 Hypertension | Universitas Padjadjaran | Not applicable | Completed | Primary Hypertension, Grade 2 | 60 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07375407) |
| January 27, 2026 | NCT07368764 | The Suitability of Tience® for Treating Acne Scars | Linio Biotech Oy | Not applicable | Active not recruiting | Acne, Acne Scars | 20 | Finland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368764) |
| January 22, 2026 | NCT07360912 | Haemorrhoidectomy With vs Without Lateral Internal Sphincterotomy | University of Baghdad | Not applicable | Completed | Grade III and IV Hemorrhoids | 120 | Iraq | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360912) |
| January 22, 2026 | NCT07360288 | Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma | TICAROS Co., Ltd. | Phase 2 | Not yet recruiting | Follicular Lymphoma (FL) | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360288) |
| January 21, 2026 | NCT07355283 | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular... | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 3 | Not yet recruiting | Relapsed/Refractory Follicular Lymphoma | 198 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355283) |
| January 15, 2026 | NCT07345377 | Study on Treatment Mechanisms and Efficacy Prediction of Individualized Transcranial Magnetic Stimulation in Adults With Irritable Bowel... | The Affiliated Hospital of Hangzhou Normal University | Not applicable | Enrolling by invitation | Irritable Bowel Syndrome (IBS), Pain, Depressive Disorder, Major, Moderate | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07345377) |
| January 15, 2026 | NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | University of Pennsylvania | Phase 1 | Recruiting | Relapsed or Refractory Follicular Lymphoma | 6 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343934) |
| January 12, 2026 | NCT07334873 | Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome | Nanfang Hospital, Southern Medical University | Not applicable | Not yet recruiting | ARDS (Moderate or Severe) | 536 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334873) |
| January 8, 2026 | NCT07328035 | Remission in Adults With Severe Asthma in Thailand | Thammasat University | Observational | Recruiting | Severe Asthma, Asthma Control Level | 230 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328035) |
| December 23, 2025 | NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Follicular Lymphoma | 34 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299149) |
| December 18, 2025 | NCT07291986 | To Compare the Clinical Outcomes of FemtoLASIK and ICL Implantation in Treating Moderate Myopia Focusing on Refractive Stability, Contrast... | Walid Osama Abdel Rahman Nour El Din | Not applicable | Completed | Myopia, Moderate | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07291986) |
| December 15, 2025 | NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies | Ipsen | Observational | Withdrawn | Follicular Lymphoma | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282548) |
| December 12, 2025 | NCT07278921 | Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of... | Andrés José Maria Ferreri | Observational | Recruiting | Relapsed/Refractory Follicular Lymphoma | 25 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07278921) |
| December 8, 2025 | NCT07270146 | Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney)... | DongE E Jiao Coporation Limited | Phase 4 | Completed | Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen... | 360 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270146) |
| December 4, 2025 | NCT07263490 | PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) | Copenhagen University Hospital, Hvidovre | Observational | Recruiting | Pre-eclampsia, Oocyte Donation, Pre-Eclampsia; Complicating Pregnancy, Pre-Eclampsia; Mild, Pre-Eclampsia, Severe... | 462 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263490) |
| December 1, 2025 | NCT07256015 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | Bristol-Myers Squibb | Observational | Active not recruiting | Psoriasis | 200 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256015) |
| November 25, 2025 | NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL, HGBCL, FL Lymphoma... | 180 | Australia, Israel, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249905) |
| November 12, 2025 | NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | France, Germany, Italy, Japan, Poland, Spain, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226843) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Paolo Caimi, MD | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| October 14, 2025 | NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Alliance for Clinical Trials in Oncology | Phase 3 | Recruiting | Astrocytoma, IDH-Mutant, Grade 3 | 408 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215910) |
| October 3, 2025 | NCT07206121 | Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery | Innoblative Designs, Inc. | Not applicable | Recruiting | Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu, Grade I, II, III | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206121) |
| October 2, 2025 | NCT07203781 | PEEP-induced Effects on Respiratory dRivE and EFfort | Radboud University Medical Center | Not applicable | Recruiting | ARDS (Moderate or Severe), Acute Hypoxemic Respiratory Failure | 20 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203781) |
| September 29, 2025 | NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Universität Münster | Phase 2 | Recruiting | Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B | 120 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197307) |
| September 24, 2025 | NCT07191249 | Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma . | Tel-Aviv Sourasky Medical Center | Phase 2 | Recruiting | Follicular Lymphoma | 40 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07191249) |
| September 24, 2025 | NCT07189806 | Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma | Hvivo | Observational | Recruiting | Asthma (Diagnosis) | 250 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189806) |
| September 23, 2025 | NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular... | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 | Not yet recruiting | Follicular Lymphoma | 228 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187960) |
| September 22, 2025 | NCT07186959 | EGPSS for Weight Management in an in Vivo Human Model | Liu Yan | Not applicable | Enrolling by invitation | Obesity, Mild | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186959) |
| September 16, 2025 | NCT07176624 | The PRE-VAIL Study | The First Hospital of Jilin University | Not applicable | Recruiting | ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission | 259 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07176624) |
| September 15, 2025 | NCT07173790 | Watch and Wait or Worry and Wait in Indolent Lymphoma | Seoul National University Hospital | Observational | Enrolling by invitation | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL), Follicular... | 250 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173790) |
| September 11, 2025 | NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | University of Maryland, Baltimore | Phase 1 | Enrolling by invitation | B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168486) |
| September 11, 2025 | NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | First Affiliated Hospital Xi'an Jiaotong University | Early phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma | 3 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168291) |
| September 11, 2025 | NCT07167862 | Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound | University of California, Irvine | Phase 4 | Recruiting | Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild | 96 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07167862) |
| September 4, 2025 | NCT07154901 | Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) | AstraZeneca | Phase 1 | Completed | Renal Impairment | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154901) |
| September 4, 2025 | NCT07154823 | A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies | Tempus AI | Observational | Recruiting | Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | 550 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154823) |
| August 19, 2025 | NCT07128641 | Odronextamab in Low Tumor Volume Advanced FL | Gottfried von Keudell, MD PhD | Phase 2 | Recruiting | Follicular Lymphoma, Lymphoma | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128641) |
| August 17, 2025 | NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not applicable | Recruiting | Follicular Lymphoma, Treatment Naive | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126678) |
| August 14, 2025 | NCT07123311 | Implementation and Evaluation of an Internet-Based Stress Management Program for Health Students in the Sfax Region | University of Sfax | Not applicable | Completed | Anxiety Depression (Mild or Not Persistent) | 148 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123311) |
| August 14, 2025 | NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL)... | 42 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121946) |
| August 11, 2025 | NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114939) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| University of Washington | 3 | July 28, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 | May 14, 2026 |
| Sun Yat-sen University | 3 | April 24, 2026 |
| AstraZeneca | 3 | April 23, 2026 |
| Mayo Clinic | 3 | March 12, 2026 |
| Novartis Pharmaceuticals | 3 | February 20, 2026 |
| GUSTAVO SALGUERO | 2 | October 20, 2026 |
| Incyte Corporation | 2 | October 1, 2026 |
| BAAT Medical Products B.V. | 2 | September 22, 2026 |
| Ruijin Hospital | 2 | July 22, 2026 |
| Merck Sharp & Dohme LLC | 2 | June 8, 2026 |
| Universitas Padjadjaran | 2 | May 14, 2026 |
| Beijing Chao Yang Hospital | 2 | March 24, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 | March 17, 2026 |
| The First Affiliated Hospital with Nanjing Medical University | 2 | February 18, 2026 |
| Eli Lilly and Company | 2 | November 12, 2025 |
| Jacobs University Bremen gGmbH | 2 | July 29, 2025 |
| Tianjin Medical University Cancer Institute and Hospital | 2 | June 22, 2025 |
| GenomeFrontier Therapeutics TW Co., Ltd. | 2 | May 22, 2025 |
| University of Nottingham | 2 | April 18, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 55 | September 18, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 37 | October 13, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 29 | October 23, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 28 | October 20, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 12 | July 30, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 5 | May 27, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 4 | May 14, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 3 | December 8, 2025 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | June 8, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 51 | October 15, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 45 | October 13, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 17 | September 22, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 16 | July 9, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 12 | July 9, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 12 | June 5, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 11 | October 22, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 9 | October 23, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 9 | July 9, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 9 | June 8, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 8 | July 9, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 7 | June 8, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 6 | June 8, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 5 | June 8, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 4 | June 8, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 4 | December 18, 2025 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 4 | October 2, 2025 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 4 | June 19, 2025 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 3 | June 29, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 3 | June 8, 2026 |
| [Chile](https://specstream.ai/data/clinical-trials/country/chile) | 3 | June 8, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 3 | April 15, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 3 | November 12, 2025 |
| [Indonesia](https://specstream.ai/data/clinical-trials/country/indonesia) | 2 | May 14, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 2 | April 9, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).